Johnson & Johnson’s Janssen Biotech has expanded its collaboration with MacroGenics, paying US$75 M upfront to license global rights to MGD015, a preclinical bispecific antibody targeting CD3 and an undisclosed tumour antigen that is being developed for the potential treatment of haematological malignancies and solid tumours. The deal comes less than 18 months after Janssen licensed MGD011, which also incorporates MacroGenics’ dual-affinity re-targeting (DART®) technology and is in Phase I development for B-cell malignancies.